This page in English

Leif Bertilsson

Anknuten

Besöksadress : Avdelningen För Klinisk Farmakologi, C1:68, Karolinska Universitetssjukhuset 14186 Stockholm
Postadress : Institutionen för laboratoriemedicin (LABMED), H5, Avdelningen för klinisk farmakologi, Avdelningen För Klinisk Farmakologi, C1:68, Karolinska Universtetssjukhuset, Huddinge 14186 Stockholm
Leveransadress : Avdelningen För Klinisk Farmakologi, C1:68, Karolinska Universitetssjukhuset 14186 Stockholm

Publikationer

Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease
Goktas Mt, Karaca Ro, Kalkisim S, Cevik L, Kilic L, Akdogan A, et al
Basic & clinical pharmacology & toxicology 2016;():-

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients
Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, et al
Journal of clinical pharmacology 2016;56(12):1538-1549

Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex
Hatta Fh, Lundblad M, Ramsjo M, Kang Jh, Roh Hk, Bertilsson L, et al
Omics : a journal of integrative biology 2015;19(6):346-53

Genetic and Clinical Factors Affecting Plasma Clozapine Concentration
Olsson E, Edman G, Bertilsson L, Hukic Ds, Lavebratt C, Eriksson Sv, et al
The primary care companion for CNS disorders 2015;17(1):-

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study
Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, et al
Pharmacogenomics 2015;16(10):1047-64

Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?
Goktaş Mt, Hatta F, Karaca O, Kalkisim S, Kilic L, Akdogan A, et al
European journal of clinical pharmacology 2015;71(10):1223-8

The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans
Bedada W, De Andrés F, Engidawork E, Pohanka A, Beck O, Bertilsson L, et al
Journal of clinical psychopharmacology 2015;35(6):694-9

High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population
Aklillu E, Djordjevic N, Carrillo Ja, Makonnen E, Bertilsson L, Ingelman-sundberg M
Omics : a journal of integrative biology 2014;18(7):446-53

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel Kd, Suda A, et al
The Journal of antimicrobial chemotherapy 2014;69(12):3311-9

Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives
Nylén H, Björkhem-bergman L, Ekström L, Roh Hk, Bertilsson L, Eliasson E, et al
Basic & clinical pharmacology & toxicology 2014;115(4):366-71

Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin
Björkhem-bergman L, Bäckström T, Nylén H, Rönquist-nii Y, Bredberg E, Andersson Tb, et al
Drug metabolism and pharmacokinetics 2014;29(4):352-5

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients
Mannheimer B, Holm J, Koukel L, Bertilsson L, Osby U, Eliasson E
European journal of clinical pharmacology 2014;70(6):695-9

Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin
Björkhem-bergman L, Bäckström T, Nylén H, Rönquist-nii Y, Bredberg E, Andersson Tb, et al
Drug metabolism and disposition: the biological fate of chemicals 2013;41(8):1488-93

Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans
Djordjevic N, Carrillo Ja, Van Den Broek Mp, Kishikawa J, Roh Hk, Bertilsson L, et al
Drug metabolism and pharmacokinetics 2013;28(2):93-7

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations
Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, et al
PloS one 2013;8(7):e67946-

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel Kd, et al
The pharmacogenomics journal 2013;13(6):484-9

Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans
Djordjevic N, Carrillo Ja, Roh Hk, Karlsson S, Ueda N, Bertilsson L, et al
Journal of clinical pharmacology 2012;52(10):1527-34

Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation
Molanaei H, Stenvinkel P, Qureshi Ar, Carrero Jj, Heimburger O, Lindholm B, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2012;68(5):571-7

Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance
Teh Lk, Bertilsson L
DRUG METABOLISM AND PHARMACOKINETICS 2012;27(1):55-67

Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes
Hatta Fh, Teh Lk, Helldén A, Hellgren Ke, Roh Hk, Salleh Mz, et al
European journal of clinical pharmacology 2012;68(7):1033-42

The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans
Helldén A, Panagiotidis G, Johansson P, Waters N, Waters S, Tedroff J, et al
European journal of clinical pharmacology 2012;68(9):1281-6

UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems
Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-sundberg M, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2012;92(2):221-7

4 beta-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
Diczfalusy U, Nylen H, Elander P, Bertilsson L
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2011;71(2):183-9

Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4 beta-hydroxycholesterol
Nylen H, Sergel S, Forsberg L, Lindemalm S, Bertilsson L, Wide K, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2011;67(7):715-22

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel Kd, Suda A, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2011;90(3):406-13

Carriers of the UGT1A4 142T > G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients
Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2010;66(5):465-74

Clinically Significant CYP2C Inhibition by Noscapine but Not by Glucosamine
Rosenborg S, Stenberg M, Otto S, Ostervall J, Masquelier M, Yue Qy, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2010;88(3):343-6

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking
Ramsjo M, Aklillu E, Bohman L, Ingelman-sundberg M, Roh Hk, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2010;66(9):871-7

CYP2D6, serotonin and suicide
Ahlner J, Zackrisson Al, Lindblom B, Bertilsson L
PHARMACOGENOMICS 2010;11(7):903-5

CYP2D6, serotonin, and suicide-a relationship?
Bertilsson L
CLINICAL PHARMACOLOGY & THERAPEUTICS 2010;88(3):304-5

Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9
Hellden A, Bergman U, Hellgren Ke, Masquelier M, Remahl In, Odar-cederlof I, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2010;66(8):791-5

Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease
Molanaei H, Carrero Jj, Heimburger O, Nordfors L, Lindholm B, Stenvinkel P, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2010;66(3):269-73

4 beta-Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin
Diczfalusy U, Kanebratt Kp, Bredberg E, Andersson Tb, Bottiger Y, Bertilsson L
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2009;67(1):38-43

Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers
Ghotbi R, Gomez A, Milani L, Tybring G, Syvanen Ac, Bertilsson L, et al
PHARMACOGENOMICS JOURNAL 2009;9(3):208-17

CLINICALLY SIGNIFICANT CYP INHIBITION BY NOSCAPINE
Rosenborg S, Stenberg M, Yue Qy, Bertilsson L, Eliasson E
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2009;:72-72

INCREASED CYP2D6 ACTIVITY MAY BE ASSOCIATED WITH VENTRICULAR ARRHYTHMIAS (VA) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (AMI)
Goryachkina K, Burbello A, Boldueva S, Bergman U, Bertilsson L
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2009;:80-80

MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs
Hilli J, Heikkinen T, Rontu R, Lehtimaki T, Kishida I, Aklillu E, et al
EUROPEAN NEUROPSYCHOPHARMACOLOGY 2009;19(5):363-70

STEADY STATE EFAVIRENZ PHARMACOKINETICS PROFILE AMONG HIV PATIENTS IN ETHIOPIA
Eyakem A, Amogne W, Yimer G, Makonnen E, Aderaye G, Bertilsson L, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2009;:6-6

THE AUTO INDUCTION OF EFAVIRENZ METABOLISM AND THE RESULTING EFFECT ON THE EFAVIRENZ STEADY STATE LEVELS IN TANZANIAN PATIENTS
Ngaimisi E, Mugusi S, Minzi O, Sasi P, Janabi M, Mugusi F, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2009;:7-7

Voriconazole Increases while Itraconazole Decreases Plasma Meloxicam Concentrations
Hynninen Vv, Olkkola Kt, Bertilsson L, Kurkinen Kj, Korhonen T, Neuvonen Pj, et al
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2009;53(2):587-92

4 beta-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
Diczfalusy U, Miura J, Roh Hk, Mirghani Ra, Sayi J, Larsson H, et al
PHARMACOGENETICS AND GENOMICS 2008;18(3):201-8

CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction
Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2008;64(12):1163-73

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4 beta-hydroxycholesterol levels
Josephson F, Bertilsson L, Bottiger Y, Flamholc L, Gisslen M, Ormaasen V, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2008;64(8):775-81

Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4 beta-Hydroxycholesterol
Kanebratt Kp, Diczfalusy U, Backstrom T, Sparve E, Bredberg E, Bottiger Y, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2008;84(5):589-94

Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine
Hynninen Vv, Olkkola Kt, Bertilsson L, Kurkinen K, Neuvonen Pj, Laine K
CLINICAL PHARMACOLOGY & THERAPEUTICS 2008;83(2):342-8

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers
Baldwin Rm, Ohlsson S, Pedersen Rs, Mwinyi J, Ingelman-sundberg M, Eliasson E, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2008;65(5):767-74

Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2008;64(4):381-5

Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI)
Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2008;64(3):275-82

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
Rosenborg So, Mwinyi J, Andersson M, Baldwin Rm, Pedersen Rs, Sim Sc, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2008;64(12):1175-9

Time course of the increase in 4 beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy
Wide K, Larsson H, Bertilsson L, Diczfalusy U
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2008;65(5):708-15

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
Ghotbi R, Christensen M, Roh Hk, Ingelman-sundberg M, Aklillu E, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2007;63(6):537-46

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited
Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, et al
PHARMACOGENETICS AND GENOMICS 2007;17(5):339-47

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2007;81(5):708-12

Experiences from pharmacogenetic testing in clinical practice
Eliasson E, Bertilsson L, Sjoqvist F
THERAPEUTIC DRUG MONITORING 2007;29(4):487-488

Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population
Hilli J, Rane A, Lundgren S, Bertilsson L, Laine K
FUNDAMENTAL & CLINICAL PHARMACOLOGY 2007;21(4):379-86

Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers
Allqvist A, Miura J, Bertilsson L, Mirghani Ra
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2007;63(2):173-9

Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: Clinical and interethnic aspects
Bertilsson L
CLINICAL PHARMACOLOGY & THERAPEUTICS 2007;82(5):606-9

Monoamine metabolites level in CSF are related to the 5-HTT gene polymorphism in treatment-resistant depression
Kishida I, Aklillu E, Kawanishi C, Bertilsson L, Agren H
EUROPEAN NEUROPSYCHOPHARMACOLOGY 2007;:S328-S328

Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression
Kishida I, Aklillu E, Kawanishi C, Bertilsson L, Agren H
NEUROPSYCHOPHARMACOLOGY 2007;32(10):2143-51

Voriconazole and fluconazole increase the exposure to oral diazepam
Saari Ti, Laine K, Bertilsson L, Neuvonen Pj, Olkkola Kt
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2007;63(10):941-9

A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
Sim Sc, Risinger C, Dahl Ml, Aklillu E, Christensen M, Bertilsson L, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2006;79(1):103-13

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo
Wennerholm A, Nordmark A, Pihlsgard M, Mahindi M, Bertilsson L, Gustafsson Ll
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2006;62(7):539-46

CYP2D6 genotype contributes to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity: CYP2D6-dopamine interaction re-visited
Ozdemir V, Bertilsson L, Reist C, Miura J, Albers Lj, Harper R, et al
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 2006;:S76-S76

CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo
Miura J, Aklillu E, Allqvist A, Gustafsson Ll, Jande M, Mirghani Ra, et al
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY 2006;21(4):A33-A33

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
Mirghani Ra, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A, et al
PHARMACOGENETICS AND GENOMICS 2006;16(9):637-45

Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin
Niemi M, Kivisto Kt, Diczfalusy U, Bodin K, Bertilsson L, Fromm Mf, et al
PHARMACOGENETICS AND GENOMICS 2006;16(8):565-8

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines
Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers Lj, Graham Je, et al
EXPERT OPINION ON PHARMACOTHERAPY 2006;7(2):119-33

Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects
Wennerholm A, Allqvist A, Svensson Jo, Gustafsson Ll, Mirghani Ra, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2005;61(2):113-8

Monoamine metabolites in CSF are related to serotonin transporter promoter gene polymorphism in treatment-resistant major depression.
Kishida I, Aklillu E, Bertilsson L, Agren H, Kawanishi C
NORDIC JOURNAL OF PSYCHIATRY 2005;59(5):413-413

Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles
Rodriguez-antona C, Sayi Jg, Gustafsson Ll, Bertilsson L, Ingelman-sundberg M
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 2005;338(1):299-305

Alprazolam as a probe for CYP3A in man using a single blood sample: Development of an LC/MS method and kinetics of parent drug, alpha- and 4-hydroxy metabolites in healthy subjects
Wennerholm A, Allqvist A, Svensson J, Gustafsson Ll, Bertilsson L, Mirghani Ra
DRUG METABOLISM REVIEWS 2004;:337-337

Dose of proton pump inhibitors and the CYP2C19 genotype
Bertilsson L
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2004;95(1):1-

Genetic polymorphisms of CYP1A2 and xanthine oxidase in ethiopians affecting expression: Characterization of novel CYP1A2 haplotypes
Aklillu E, Carrillo Ja, Mekonen E, Bertilsson L, Ingelman-sundberg M
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY 2004;31(11):A220-A220

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study
Kawanishi C, Lundgren S, Agren H, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2004;59(11):803-7

Omeprazole treatment of Korean patients: Effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes
Roh Hk, Kim Ps, Lee Dh, Tybring G, Sagar M, Park Cs, et al
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2004;95(3):112-9

Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy
Laine K, Kytola J, Bertilsson L
THERAPEUTIC DRUG MONITORING 2004;26(6):685-7

Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians
Dalen P, Dahl Ml, Roh Hk, Tybring G, Eichelbaum M, Wilkinson Gr, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2003;55(6):630-4

Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity
Hartter S, Nordmark A, Rose Dm, Bertilsson L, Tybring G, Laine K
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2003;56(6):679-82

Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
Aklillu E, Carrillo Ja, Makonnen E, Hellman K, Pitarque M, Bertilsson L, et al
MOLECULAR PHARMACOLOGY 2003;64(3):659-69

Individualized medicine - Implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders
Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M
PHARMACOPSYCHIATRY 2003;:S235-43

Inhibitory profile of the malarial drug amodiaquine on the metabolism of four CYP450 probe drugs
Wennerholm A, Bertilsson L, Gustafsson Ll
DRUG METABOLISM REVIEWS 2003;:52-52

Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity
Hellman K, Roos E, Osterlund A, Wahlberg A, Gustafsson Ll, Bertilsson L, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2003;56(3):337-40

Metabolism and elimination of quinine in healthy volunteers
Mirghani Ra, Hellgren U, Bertilsson L, Gustafsson Ll, Ericsson O
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2003;59(5-6):423-7

Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes
Herrlin K, Yasui-furukori N, Tybring G, Widen J, Gustafsson Ll, Bertilsson L
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2003;56(4):415-21

Persistent mood disorders and cytochrome P450 2D6: influence of the CYP2D6 gene duplication on the development of persistence
Kawanishi C, Agren H, Bertilsson L
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY 2003;18(3):180-180

Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man
Mirghani Ra, Ericsson O, Tybring G, Gustafsson Ll, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2003;59(1):23-8

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
Christensen M, Andersson K, Dalen P, Mirghani Ra, Muirhead Gj, Nordmark A, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2003;73(6):517-28

Xanthine oxidase activity is influenced by environmental factors in Ethiopians
Aklillu E, Carrillo Ja, Makonnen E, Bertilsson L, Ingelman-sundberg M
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2003;59(7):533-6

Comparison of haloperidol plasma levels between Swedish, Korean and Japanese psychiatric patients
Morita S, Shimoda K, Roh Hk, Someya T, Shibasaki M, Hirokane G, et al
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY 2002;:S6-S7

Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man?
Ursing C, Hartter S, Von Bahr C, Tybring G, Bertilsson L, Rojdmark S
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 2002;25(5):459-62

Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
Aklillu E, Herrlin K, Gustafsson Ll, Bertilsson L, Ingelman-sundberg M
PHARMACOGENETICS 2002;12(5):375-83

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)
Christensen M, Tybring G, Mihara K, Yasui-furokori N, Carrillo Ja, Ramos Si, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2002;71(3):141-52

Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson L, Dahl Ml, Dalen P, Al-shurbaji A
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2002;53(2):111-22

The African-specific C Upsilon P2D6*17 allele encodes an enzyme with changed substrate specificity
Wennerholm A, Dandara C, Sayi J, Svensson Jo, Abdi Ya, Ingelman-sundberg M, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2002;71(1):77-88

The single nucleotide polymorphism T1128C in the signal peptide of neuropeptide Y (NPY) was not identified in a Korean population
Ding B, Bertilsson L, Wahlestedt C
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS 2002;27(3):211-2

Antiepileptic drugs increase plasma levels of 4 beta-hydroxycholesterol in humans - Evidence for involvement of cytochrome P450 3A4
Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al
JOURNAL OF BIOLOGICAL CHEMISTRY 2001;276(42):38685-9

Characterization of the CYP2D6*29 allele commonly present in a blade Tanzanian population causing reduced catalytic activity
Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson Ll, Ingelman-sundberg M
PHARMACOGENETICS 2001;11(5):417-27

CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline
Laine K, Anttila M, Nyman L, Wahlberg A, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2001;57(2):137-42

Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry
Hartter S, Morita S, Bodin K, Ursing C, Tybring G, Bertilsson L
THERAPEUTIC DRUG MONITORING 2001;23(3):282-6

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test
Laine K, Tybring G, Hartter S, Andersson K, Svensson Jo, Widen J, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2001;70(4):327-35

Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation
Alvan G, Bertilsson L, Dahl Ml, Ingelman-sundberg M, Sjoqvist F
DRUG METABOLISM AND DISPOSITION 2001;29(4):580-5

Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study
Hartter S, Ursing C, Morita S, Tybring G, Von Bahr C, Christensen M, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2001;70(1):10-6

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
Roh Hk, Chung Jy, Oh Dy, Park Cs, Svensson Jo, Dahl Ml, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2001;52(3):265-71

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients
Roh Hk, Kim Ce, Chung Wg, Park Cs, Svensson Jo, Bertilsson L
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2001;57(9):671-5

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
Scordo Mg, Spina E, Romeo P, Dahl Ml, Bertilsson L, Johansson I, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2000;56(9-10):679-83

Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
Sagar M, Tybring G, Dahl Ml, Bertilsson L, Seensalu R
GASTROENTEROLOGY 2000;119(3):670-6

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine
Carrillo Ja, Christensen M, Ramos Si, Alm C, Dahl Ml, Benitez J, et al
THERAPEUTIC DRUG MONITORING 2000;22(4):409-17

Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P-450 CYP1A2 and CYP2C19 hydroxylate melatonin
Von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Rojdmark S
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2000;56(2):123-7

Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes
Dalen P, Dahl Ml, Andersson K, Bertilsson L
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2000;49(2):180-4

No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
Laine K, Tybring G, Bertilsson L
CLINICAL PHARMACOLOGY & THERAPEUTICS 2000;68(2):151-9

Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
Sagar M, Bertilsson L, Stridsberg M, Kjellin A, Mardh S, Seensalu R
ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2000;14(11):1495-502

Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype
Herrlin K, Massele Ay, Rimoy G, Alm C, Rais M, Ericsson O, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 2000;68(2):189-98

Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders
Lidberg L, Belfrage H, Bertilsson L, Evenden Mm, Asberg M
ACTA PSYCHIATRICA SCANDINAVICA 2000;101(5):395-402

The effects of long-term omeprazole therapy on gastrin, pepsinogen I, and chromogranin A concentrations are related to CYP2C19 polymorphism.
Sagar Me, Bertilsson L, Stridsberg M, Mard S, Kjellin A, Seensalu R
GASTROENTEROLOGY 2000;118(4):A884-A884

Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype
Wennerholm A, Johansson I, Massele Ay, Jande M, Alm C, Aden-abdi Y, et al
PHARMACOGENETICS 1999;9(6):707-14

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes
Dalen P, Dahl Ml, Eichelbaum M, Bertilsson L, Wilkinson Gr
PHARMACOGENETICS 1999;9(6):697-706

Effect of CYP2C19 polymorphism on serum levels of vitamin B-12 in patients on long-term omeprazole treatment
Sagar M, Janczewska I, Ljungdahl A, Bertilsson L, Seensalu R
ALIMENTARY PHARMACOLOGY & THERAPEUTICS 1999;13(4):453-8

Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance
Brynne N, Svanstrom C, Aberg-wistedt A, Hallen B, Bertilsson L
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1999;48(4):553-63

Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients
Persson I, Johansson I, Lou Yc, Yue Qy, Duan Ls, Bertilsson L, et al
INTERNATIONAL JOURNAL OF CANCER 1999;81(3):325-9

High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands
Kaneko A, Lum Jk, Yaviong J, Takahashi N, Ishizaki T, Bertilsson L, et al
PHARMACOGENETICS 1999;9(5):581-90

Inhibition of CYP3A4 does not influence Aromasin (R) (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV)
Jannuzzo Mg, Spinelli R, Poggesi I, Cicioni P, Bottiger Y, Bertilsson L
EUROPEAN JOURNAL OF CANCER 1999;:S294-S294

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity
Brynne N, Forslund C, Hallen B, Gustafsson Ll, Bertilsson L
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1999;48(4):564-72

Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine effect of alpha(2)-adrenoceptor blockade
Linner L, Arborelius L, Nomikos Gg, Bertilsson L, Svensson Th
BIOLOGICAL PSYCHIATRY 1999;46(6):766-74

Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients
Shimoda K, Jerling M, Bottiger Y, Yasuda S, Morita S, Bertilsson L
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY 1999;19(5):393-400

Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxydebrisoquine in urine for CYP2D6 phenotyping
Svensson Jo, Bertilsson L
PHARMACOGENETICS 1999;9(4):529-31

Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
Mihara K, Svensson Ush, Tybring G, Hai Tn, Bertilsson L, Ashton M
FUNDAMENTAL & CLINICAL PHARMACOLOGY 1999;13(6):671-5

Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
Bernal Ml, Sinues B, Johansson I, Mclellan Ra, Wennerholm A, Dahl Ml, et al
PHARMACOGENETICS 1999;9(5):657-60

The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo
Mirghani Ra, Hellgren U, Westerberg Pa, Ericsson O, Bertilsson L, Gustafsson Ll
CLINICAL PHARMACOLOGY & THERAPEUTICS 1999;66(5):454-60

Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole
Brynne N, Bottiger Y, Hallen B, Bertilsson L
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1999;47(2):145-50

10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional C Upsilon P2D6 genes
Dalen P, Dahl Ml, Ruiz Mlb, Nordin J, Bertilsson L
CLINICAL PHARMACOLOGY & THERAPEUTICS 1998;63(4):444-52

1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans
Eiermann B, Edlund Po, Tjernberg A, Dalen P, Dahl Ml, Bertilsson L
DRUG METABOLISM AND DISPOSITION 1998;26(11):1096-101

Artemisinin induces omeprazole metabolism in human beings
Svensson Ush, Ashton M, Hai Tn, Bertilsson L, Huong Dx, Van Huong N, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 1998;64(2):160-7

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
Herrlin K, Massele Ay, Jande M, Alm C, Tybring G, Abdi Ya, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 1998;64(4):391-401

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection
Sagar M, Seensalu R, Tybring G, Dahl Ml, Bertilsson L
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 1998;33(10):1034-8

CYP2D6 polymorphism is not crucial for the disposition of selegiline
Scheinin H, Anttila M, Dahl Ml, Karnani H, Nyman L, Taavitsainen P, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 1998;64(4):402-11

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine
Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J
CLINICAL PHARMACOLOGY & THERAPEUTICS 1998;63(5):529-39

Interethnic differences in the CYP2D6 polymorphism with emphasis on gene duplication/amplification
Bertilsson L
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 1998;358(1):R15-R15

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors
Arlander E, Ekstrom G, Alm C, Carrillo Ja, Bielenstein M, Bottiger Y, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 1998;64(5):484-91

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes
Yue Qy, Zhong Zh, Tybring G, Dalen P, Dahl Ml, Bertilsson L, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 1998;64(4):384-90

The effect of omeprazole on intragastric pH and gastrin levels is determined by the CYP2C19 polymorphism more than by H-pylori infection in patients with acid related disease.
Sagar M, Tybring G, Dahl Ml, Bertilsson L, Seensalu R
GASTROENTEROLOGY 1998;114(4):A273-A273

An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoin
Tyring G, Nordin J, Bergman T, Bertilsson L
PHARMACOGENETICS 1997;7(5):355-60

Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19
Bertilsson L, Tybring G, Widen J, Chang M, Tomson T
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1997;44(2):186-9

Clozapine metabolism in vitro is catalyzed by CYP1A2 and CYP3A4
Eiermann B, Engel G, Bertilsson L
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 1997;355(4):460-460

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects
Tybring G, Bottiger Y, Widen J, Bertilsson L
CLINICAL PHARMACOLOGY & THERAPEUTICS 1997;62(2):129-37

Individual metabolism of omeprazole is determined by the genotype of the enzyme CYP2C19 without relation to H-pylori infection.
Sagar M, Bertilsson L, Dahl Ml, Tybring G, Seensalu R
GASTROENTEROLOGY 1997;112(4):A275-A275

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin
Bottiger Y, Tybring G, Gotharson E, Bertilsson L
CLINICAL PHARMACOLOGY & THERAPEUTICS 1997;62(4):384-91

In vitro and in vivo studies on the disposition of mirtazapine in humans
Dahl Ml, Voortman G, Alm C, Elwin Ce, Delbressine L, Vos R, et al
CLINICAL DRUG INVESTIGATION 1997;13(1):37-46

Pharmacogenetics of antidepressants: Clinical aspects
Bertilsson L, Dahl Ml, Tybring G
ACTA PSYCHIATRICA SCANDINAVICA 1997;:14-21

Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state
Shimoda K, Yasuda S, Morita S, Shibasaki M, Someya T, Bertilsson L, et al
PSYCHIATRY AND CLINICAL NEUROSCIENCES 1997;51(1):35-41

The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients
Mihara K, Otani K, Tybring G, Dahl Ml, Bertilsson L, Kaneko S
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY 1997;17(6):467-71

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
Eiermann B, Engel G, Johansson I, Zanger Um, Bertilsson L
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1997;44(5):439-46

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelmansundberg M
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1996;42(6):713-9

Antidepressants and drug-metabolizing enzymes - Expert group report
Meyer Ua, Amrein R, Balant Lp, Bertilsson L, Eichelbaum M, Guentert Tw, et al
ACTA PSYCHIATRICA SCANDINAVICA 1996;93(2):71-9

CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
Roh Hk, Dahl Ml, Tybring G, Yamada H, Cha Yn, Bertilsson L
PHARMACOGENETICS 1996;6(6):547-51

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population
Roh Hk, Dahl Ml, Johansson I, Ingelmansundberg M, Cha Yn, Bertilsson L
PHARMACOGENETICS 1996;6(5):441-7

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity
Carrillo Ja, Dahl Ml, Svensson Jo, Alm C, Rodriguez I, Bertilsson L
CLINICAL PHARMACOLOGY & THERAPEUTICS 1996;60(2):183-90

Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelmansundberg M
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 1996;278(1):441-6

Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans
Bottiger Y, Dostert P, Benedetti Ms, Bani M, Fiorentini F, Casati M, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1996;42(6):707-11

Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders
Bertilsson L, Dahl Ml
CNS DRUGS 1996;5(3):200-223

S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among ethiopians
Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelmansundberg M
PHARMACOGENETICS 1996;6(6):521-6

Steady state plasma levels of nortriptyline and its 1.0-hydroxy metabolite: Relationship to the CYP2D6 genotype
Dahl Ml, Bertilsson L, Nordin C
PSYCHOPHARMACOLOGY 1996;123(4):315-9

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol
Jerling M, Dahl Ml, Abergwistedt A, Liljenberg B, Landell Ne, Bertilsson L, et al
CLINICAL PHARMACOLOGY & THERAPEUTICS 1996;59(4):423-8

ACTIVE HYDROXYMETABOLITES OF ANTIDEPRESSANTS - EMPHASIS ON E-10-HYDROXY-NORTRIPTYLINE
Nordin C, Bertilsson L
CLINICAL PHARMACOKINETICS 1995;28(1):26-40

CODEINE METABOLISM IN 3 ORIENTAL POPULATIONS - A PILOT-STUDY IN CHINESE, JAPANESE AND KOREANS
Yue Qy, Svensson Jo, Sawe J, Bertilsson L
PHARMACOGENETICS 1995;5(3):173-7

D-2 DOPAMINE-RECEPTOR OCCUPANCY DURING LOW-DOSE TREATMENT WITH HALOPERIDOL DECANOATE
Nyberg S, Farde L, Halldin C, Dahl Ml, Bertilsson L
AMERICAN JOURNAL OF PSYCHIATRY 1995;152(2):173-8

ENANTIOSELECTIVE DETERMINATION OF MIANSERIN AND ITS DESMETHYL METABOLITE IN PLASMA DURING TREATMENT OF DEPRESSED JAPANESE PATIENTS
Tybring G, Otani K, Kaneko S, Mihara K, Fukushima Y, Bertilsson L
THERAPEUTIC DRUG MONITORING 1995;17(5):516-21

GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS
Dahl Ml, Yue Qy, Roh Hk, Johansson I, Sawe J, Sjoqvist F, et al
PHARMACOGENETICS 1995;5(3):159-64

GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19
Bertilsson L
CLINICAL PHARMACOKINETICS 1995;29(3):192-209

INTERACTION BETWEEN CAFFEINE AND CLOZAPINE - COMMENT
Carrillo Ja, Jerling M, Bertilsson L
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY 1995;15(5):376-7

NO EFFECT ON PLASMA CARBAMAZEPINE CONCENTRATION WITH CONCOMITANT OMEPRAZOLE TREATMENT
Bottiger Y, Bertilsson L
CLINICAL DRUG INVESTIGATION 1995;9(3):180-181

PHARMACOGENETICS IN CLINICAL-PHARMACOLOGY AND TOXICOLOGY
Inaba T, Nebert Dw, Burchell B, Watkins Pb, Goldstein Ja, Bertilsson L, et al
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 1995;73(3):331-8

PHENOTYPING AND GENOTYPING OF S-MEPHENYTOIN HYDROXYLASE (CYTOCHROME-P450 2C19) IN A SHONA POPULATION OF ZIMBABWE
Masimirembwa C, Bertilsson L, Johansson I, Hasler Ja, Ingelmansundberg M
CLINICAL PHARMACOLOGY & THERAPEUTICS 1995;57(6):656-61

ULTRARAPID HYDROXYLATION OF DEBRISOQUINE IN A SWEDISH POPULATION - ANALYSIS OF THE MOLECULAR-GENETIC BASIS
Dahl Ml, Johansson I, Bertilsson L, Ingelmansundberg M, Sjoqvist F
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 1995;274(1):516-20

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
Chang M, Dahl Ml, Tybring G, Gotharson E, Bertilsson L
PHARMACOGENETICS 1995;5(6):358-63

Visa alla publikationer